These are really good numbers in the US our target market, with quarter on quarter growth of 68% and half yearly growth of 43%. This would mean full year US sales of approximately US$210M.
The hospital purchasing departments will take up the generic, why would they knock back a 10% saving. The longevity is protected as there are no injectable competitors, if one attempts it the time frame and risk reward would only be contemplated on the basis of a larger market. Either way ACL wins.
Unfortunately as usual the market is not interested in this news it's all down to FDA approval.
- Forums
- ASX - By Stock
- arixtra sales
These are really good numbers in the US our target market, with...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable